First Light Asset Management LLC Decreases Stock Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

First Light Asset Management LLC reduced its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 2.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,805,184 shares of the company's stock after selling 134,948 shares during the quarter. Centessa Pharmaceuticals makes up approximately 9.2% of First Light Asset Management LLC's holdings, making the stock its 2nd biggest position. First Light Asset Management LLC owned approximately 4.40% of Centessa Pharmaceuticals worth $97,237,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after purchasing an additional 865 shares in the last quarter. Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after acquiring an additional 5,316 shares in the last quarter. XTX Topco Ltd increased its position in shares of Centessa Pharmaceuticals by 122.9% in the fourth quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after acquiring an additional 12,506 shares during the last quarter. Finally, Voya Investment Management LLC bought a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $497,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Morgan Stanley restated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim reiterated a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $27.71.

Insider Activity at Centessa Pharmaceuticals

In related news, CTO Tia L. Bush sold 11,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $185,460.00. Following the transaction, the chief technology officer now directly owns 121,503 shares of the company's stock, valued at approximately $2,048,540.58. This trade represents a 8.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Karen M. Anderson sold 6,471 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $109,101.06. Following the completion of the sale, the insider now directly owns 54,322 shares of the company's stock, valued at $915,868.92. This represents a 10.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 219,824 shares of company stock worth $3,581,039 in the last ninety days. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA traded up $0.11 during mid-day trading on Friday, reaching $13.61. 749,858 shares of the company were exchanged, compared to its average volume of 614,268. The stock has a market capitalization of $1.81 billion, a P/E ratio of -8.90 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company's 50-day simple moving average is $14.17 and its 200-day simple moving average is $15.79. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. As a group, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.